Loren Data's SAM Daily™

FBO DAILY ISSUE OF FEBRUARY 20, 2004 FBO #0816
SOLICITATION NOTICE

A -- Department of Defense (DOD) Fiscal Year 2004 (FY04) Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA)

Notice Date

2/18/2004
 

Notice Type

Solicitation Notice
 

Contracting Office

US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
 

ZIP Code

21702-5014
 

Solicitation Number

CML04-TDA
 

Response Due

7/27/2004
 

Archive Date

9/25/2004
 

Point of Contact

joseph little, 301-619-2546
 

E-Mail Address

US Army Medical Research Acquisition Activity
(joseph.little@det.amedd.army.mil)
 

Small Business Set-Aside

N/A
 

Description

This program is administered by the US Army Medical Research and Materiel Command through the office of the Congressionally Directed Medical Research Programs (CDMRP). The objectives of the FY04 CMLRP are to improve (1) the understanding of the basic science of CML, (2) the diagnosis of CML, (3) the treatment of CML, and (4) the quality of life for individuals and their families living with CML. The intent of the Therapeutic Development Award mechanism is to sponsor the preclinical assessment of therapeutics, as well as the development of tools for the preclinical evaluation in model systems for CML. The overall goal of this award mechanism is to allow CML investigators to develop the means to analyze preclinical efficacy of novel and existing agents and/or to generate the preclinical data necessary to conduct clinical trials after completion of the proposed research. The Therapeutic Development Award is restricted to research in CML. The proposed studies are expected to be empirical in nature and product driven, but may have a hypothesis-driven approach provided the focus is on therapeutics. It is anticipated that the agents, model systems, or data generated from these awards will lead to the advancement of therapeutics novel to CML and to the development of a broad platform on which to test future therapies. The ultimate goal is to significantly move closer to the development of new therapeuti cs for CML. The announcement was released on 18 Feb 2004 with a submission deadline of 27 July 2004, 5:00 pm Eastern Time. Detailed descriptions of this funding mechanism, evaluation criteria, and submission requirements can be found in the FY04 CML Progra m Announcement and can be downloaded from the CDMRP website (http://cdmrp.army.mil). All applicants will be required to submit one electronic version of their proposal as a PDF file. All documents may be downloaded from the CDMRP website. The website also contains further information about the CMLRP, CMLRP awardees, previous CMLRP Program Announcements, and other CDMRP-sponsored programs and events. Questions related to the Program, proposal format or required documentation can be addressed to the CDMRP at 301-619-7079, FAX at 301-619-7792 or email at cdmrp.pa@det.amedd.army.mil.
 

Web Link

Link to FedBizOpps document.
(http://www.eps.gov/spg/USA/USAMRAA/DAMD17/CML04-TDA/listing.html)
 

Place of Performance

Address: US Army Medical Research Acquisition Activity ATTN: MCMR-AAA, 820 Chandler Street Frederick MD

Zip Code: 21702-5014

Country: US
 

Record

SN00524305-F 20040220/040218224407 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |